Dr. David L. Wirta, MD
Ophthalmology (Ophthalmology Physician)
At a glance
- Medical school
- University of California, Geffen School of Medicine (1993)
- Years since graduation
- 33
- In the NPI registry since
- 2006
Licensed in California since 1995, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1993Medical school: University of California, Geffen School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Ophthalmology Physician primary
CA license G81350 (first issued 1995; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- David L Wirta MD Inc (2 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Latanoprost Other prescribers in Newport Beach, CA | 103 |
| Timolol Maleate Other prescribers in Newport Beach, CA | 43 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 8 companies reported 33 payments worth $29,441 in total to this clinician.
| Alcon Vision LLC | $19,282 |
|---|---|
| Oyster Point Pharma, Inc. | $4,395 |
| Bausch & Lomb Americas Inc. | $3,877 |
| AbbVie Inc. | $875 |
| Alcon Research LLC | $782 |
| Glaukos Corporation | $135 |
| Thea Pharma Inc. | $48.03 |
| Harrow Eye, LLC | $47.37 |
| Consulting Fee | $25,470 |
|---|---|
| Travel and Lodging | $2,067 |
| Food and Beverage | $1,104 |
| Compensation for services other than consulting (speaking, faculty) | $800 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Alcon Vision LLC Aug 7, 2025 | Consulting Fee TRYPTYR · Ophthalmology | $6,000 |
| Alcon Vision LLC Jul 24, 2025 | Consulting Fee TRYPTYR · Ophthalmology | $5,000 |
| Oyster Point Pharma, Inc. Oct 1, 2025 | Consulting Fee | $4,395 |
| Bausch & Lomb Americas Inc. Oct 6, 2025 | Consulting Fee | $3,825 |
| Alcon Vision LLC Aug 7, 2025 | Consulting Fee TRYPTYR · Ophthalmology | $1,600 |
| Alcon Vision LLC Jul 10, 2025 | Consulting Fee | $800 |
| Alcon Vision LLC Jan 23, 2025 | Consulting Fee | $800 |
| Alcon Vision LLC Apr 24, 2025 | Consulting Fee TRYPTYR · Ophthalmology | $800 |
| Alcon Vision LLC May 8, 2025 | Compensation for services other than consulting (speaking, faculty) TRYPTYR · Ophthalmology | $800 |
| AbbVie Inc. Nov 3, 2025 | Consulting Fee | $650 |
All 20 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Alcon Vision LLC Nov 6, 2025 | Consulting Fee TRYPTYR · Ophthalmology | $600 |
| AbbVie Inc. Nov 3, 2025 | Consulting Fee | $650 |
| Alcon Vision LLC Oct 9, 2025 | Consulting Fee | $400 |
| Bausch & Lomb Americas Inc. Oct 6, 2025 | Consulting Fee | $3,825 |
| Oyster Point Pharma, Inc. Oct 1, 2025 | Consulting Fee | $4,395 |
| AbbVie Inc. Sep 19, 2025 | Travel and Lodging travel to IRVINE, CA · in-kind | $55.00 |
| Alcon Vision LLC Aug 7, 2025 | Consulting Fee TRYPTYR · Ophthalmology | $6,000 |
| Alcon Vision LLC Aug 7, 2025 | Consulting Fee TRYPTYR · Ophthalmology | $1,600 |
| Alcon Vision LLC Jul 24, 2025 | Consulting Fee TRYPTYR · Ophthalmology | $5,000 |
| Alcon Vision LLC Jul 23, 2025 | Travel and Lodging TRYPTYR · Ophthalmology · travel to Fort Worth, TX · in-kind | $523 |
| Alcon Vision LLC Jul 23, 2025 | Travel and Lodging EYSUVIS · Ophthalmology · travel to Fort Worth, TX · in-kind | $338 |
| Alcon Vision LLC Jul 23, 2025 | Travel and Lodging EYSUVIS · Ophthalmology · travel to Fort Worth, TX · in-kind | $260 |
| Alcon Vision LLC Jul 18, 2025 | Travel and Lodging TRYPTYR · Ophthalmology · travel to Fort Worth, TX · in-kind | $540 |
| Alcon Vision LLC Jul 18, 2025 | Travel and Lodging travel to Fort Worth, TX · in-kind | $241 |
| Alcon Vision LLC Jul 18, 2025 | Travel and Lodging travel to Fort Worth, TX · in-kind | $110 |
| Alcon Vision LLC Jul 10, 2025 | Consulting Fee | $800 |
| Alcon Research LLC Jul 10, 2025 | Consulting Fee TRYPTYR · Ophthalmology | $600 |
| Alcon Vision LLC May 8, 2025 | Compensation for services other than consulting (speaking, faculty) TRYPTYR · Ophthalmology | $800 |
| Alcon Vision LLC Apr 24, 2025 | Consulting Fee TRYPTYR · Ophthalmology | $800 |
| Alcon Vision LLC Jan 23, 2025 | Consulting Fee | $800 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 22 industry-funded studies in 2025, from 8 companies. The companies reported $3,067,726 in research payments for these studies, mostly to the institutions running them.
- A Randomized, Multicenter, Double-Masked, Active-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% With Sodium Hyaluronate Relative to Lumify in Adul…
Bausch & Lomb Americas Inc. - A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL)
AbbVie Inc. · Completed · NCT06834789 - A Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic Ointment
Oyster Point Pharma, Inc. · Terminated · NCT06400511 - Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances
Oyster Point Pharma, Inc. · Completed · NCT06349759 - OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual Acuity
Oyster Point Pharma, Inc. · Recruiting · NCT07140783 - COMET-Basal Tear Study
Alcon Research LLC - An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye
Vanda Pharmaceuticals Inc. - Evaluate Efficacy and Safety of POS to Improve Distance-corrected Near Visual in Participants With Presbyopia
Oyster Point Pharma, Inc. · Completed · NCT06542497 - A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular dege…
Boehringer Ingelheim Pharmaceuticals, Inc. - AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension
AbbVie Inc. · Active, not recruiting · NCT04499248
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.